CD4+ T-Cell Recognition of Mutated B-RAF in Melanoma Patients Harboring the V599E Mutation

Melinda S. Sharkey, Gregory Lizée, Monica I. Gonzales, Sima Patel, Suzanne L. Topalian

Research output: Contribution to journalArticle

Abstract

The potential of antigen-directed cancer immunotherapy has not been fully realized, perhaps because many commonly targeted tumor associated proteins are not essential to maintaining the malignant cell phenotype. A constitutively activating mutation in the signaling molecule BRAF is expressed frequently in melanomas and may play an important role in the biology of this disease. A 29-mer B-Raf peptide incorporating the V599E mutation was used for in vitro stimulation of lymphocytes derived from melanoma patients, generating MHC class II-restricted CD4+ T cells specific for this peptide as well as for melanoma cells expressing B-Raf V599E. Mutated B-Raf exemplifies targets that may be ideal for immunotherapy.

Original languageEnglish (US)
Pages (from-to)1595-1599
Number of pages5
JournalCancer Research
Volume64
Issue number5
DOIs
StatePublished - Mar 1 2004

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'CD4<sup>+</sup> T-Cell Recognition of Mutated B-RAF in Melanoma Patients Harboring the V599E Mutation'. Together they form a unique fingerprint.

  • Cite this